A Study to Assess the Pharmacokinetics and Safety of Different Forms and Formulations of AZD9496 in Healthy Subjects

A phase 1, open-label, single centre study to assess the pharmacokinetics, Safety and tolerability of different forms, formulations and doses of AZD9496 in healthy volunteers. This is a fixed sequence study with 5-sequential treatment periods. Each subject will receive 5 single doses of AZD9496 in different forms, formulations and doses. * Treatment period one will assess AZD9496 Variant A: 100mg. * Treatment period two will assess AZD9496 Reference form: 100mg. * Treatment period 3 will assess one of AZD9496 Variants, B, C or D: 100mg. * Treatment period 4 will assess one of AZD9496 Variants, B, C or D: 100mg. * Treatment period 5 will assess one of AZD9496 Variants A, B, C or D: \*300mg. \*Based on a review of pharmacokinetic and safety results from Treatment Periods 1, 3 and 4, a lower dose of 200 mg may be administered in Treatment Period 5.